Baseline characteristics for patients with DXA measurements at each time point
| Baseline characteristics | Women | Men | ||||||||
| Patients with data at inclusion | Patients with data at 2 years | Patients with data at 5 years | Patients with data at 10 years | Patients with complete DXA data | Patients with data at inclusion | Patients with data at 2 years | Patients with data at 5 years | Patients with data at 10 years | Patients with complete DXA data | |
| Number | 157 | 138 | 122 | 89 | 83 | 63 | 58 | 51 | 33 | 31 |
| Age (years) mean (SD) | 58.5 (15.6) | 58.2 (15.7) | 58.5 (15.2) | 56.4 (14.3) | 56.6 (14.2) | 63.2 (11.1) | 62.3 (11.4) | 61.0 (11.3) | 58.6 (11.5) | 58.4 (11.8) |
| Duration of symptoms (months) mean (SD) | 7.5 (2.9) | 7.5 (2.9) | 7.4 (2.8) | 7.5 (3.0) | 7.6 (2.9) | 7.1 (2.8) | 7.0 (2.8) | 7.0 (2.9) | 7.2 (2.7) | 7.0 (2.7) |
| BMI (kg/m2) mean (SD) | 24.9 (3.9) | 25.0 (3.9) | 25.2 (4.0) | 25.7 (4.1) | 25.7 (4.0) | 25.3 (3.6) | 25.9 (3.9) | 25.9 (3.8) | 25.9 (4.1) | 25.5 (3.7) |
| Smoking ever n (%) | 93 (62.4) | 80 (60.2) | 69 (59.5) | 50 (60.2) | 47 (59.5) | 54 (87.1) | 48 (84.2) | 41 (83.7) | 26 (81.3) | 24 (80.0) |
| Postmenopausal n (%) | 113 (73.4) | 99 (72.8) | 92 (76.7) | 64 (73.6) | 60 (74.1) | NA | NA | NA | NA | NA |
| RF positive n (%) | 93 (59.2) | 79 (57.2) | 75 (61.5) | 53 (59.6) | 49 (59.0) | 44 (69.8) | 39 (67.2) | 38 (74.5) | 25 (75.8) | 24 (77.4) |
| Anti-CCP positive n (%) | 79 (57.2) | 70 (56.5) | 61 (55.5) | 43 (54.4) | 40 (53.3) | 32 (61.5) | 30 (63.8) | 27 (65.9) | 16 (61.5) | 15 (62.5) |
| CRP (mg/L) median (IQR) | <9.0 (<9.0; 22.0) | <9.0 (<9.0; 17.3) | <9.0 (<9.0; 20.5) | <9.0 (<9.0; 16.0) | <9.0 (<9.0; 16.0) | 13.0 (<9.0; 33.0) | 11.5 (<9.0; 33.3) | 13.0 (<9.0; 34.0) | 10.0 (<9.0; 34.5) | 14.0 (<9.0; 35.0) |
| ESR (mm) median (IQR) | 21.0 (10.0; 43.0) | 20.0 (10.0; 34.3) | 21.0 (10.8; 39.3) | 20.0 (10.0; 32.0) | 18.0 (10.0; 30.0) | 22.0 (10.0; 46.0) | 20.0 (10.0; 46.5) | 24.0 (11.0; 52.0) | 18.0 (10.0; 43.0) | 18.0 (10.0; 46.0) |
| Erosions n (%) | 21 (13.4) | 20 (14.5) | 18 (14.8) | 14 (15.7) | 14 (16.9) | 11 (17.5) | 12 (20.7) | 12 (23.5) | 10 (30.3) | 9 (29.0) |
| HAQ median (IQR) | 0.75 (0.38; 1.25) | 0.75 (0.38; 1.25) | 0.82 (0.38; 1.25) | 0.75 (0.38; 1.13) | 0.75 (0.38; 1.13) | 0.63 (0.13; 1.13) | 0.75 (0.25; 1.13) | 0.75 (0.25; 1.13) | 0.75 (0.25; 1.13) | 0.75 (0.25; 1.13) |
| DAS28 mean (SD) | 4.63 (1.37) | 4.55 (1.40) | 4.59 (1.35) | 4.48 (1.38) | 4.37 (1.35) | 4.57 (1.48) | 4.66 (1.49) | 4.70 (1.52) | 4.61 (1.54) | 4.63 (1.59) |
| VAS global (mm) mean (SD) | 43.3 (27.1) | 41.1 (26.9) | 43.2 (27.0) | 41.4 (25.2) | 40.0 (25.2) | 43.3 (26.1) | 44.8 (26.4) | 43.0 (25.6) | 42.8 (26.6) | 44.7 (26.2) |
| VAS pain (mm) mean (SD) | 40.3 (25.6) | 38.4 (25.6) | 39.3 (25.9) | 37.9 (24.9) | 36.6 (24.8) | 42.9 (28.7) | 44.3 (28.7) | 42.8 (29.0) | 41.1 (28.6) | 42.7 (28.7) |
| sDMARDs n (%) | 128 (81.5) | 115 (83.3) | 102 (83.6) | 75 (84.3) | 69 (83.1) | 54 (85.7) | 49 (84.5) | 45 (88.2) | 29 (87.9) | 28 (90.3) |
| bDMARDs n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Corticosteroids n (%) | 57 (36.3) | 49 (35.5) | 39 (32.0) | 31 (34.8) | 27 (32.5) | 31 (49.2) | 26 (44.8) | 24 (47.1) | 14 (42.4) | 14 (45.2) |
| Calcium and D-vitamin n (%) | 50 (33.1) | 47 (34.8) | 36 (30.3) | 26 (30.2) | 24 (30.0) | 16 (26.7) | 16 (28.1) | 14 (28.6) | 10 (31.3) | 10 (33.3) |
| Bisphosphonates n (%) | 5 (3.3) | 6 (4.4) | 5 (4.2) | 2 (2.3) | 2 (2.5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0.0) |
| HRT n (%) | 24 (15.8) | 23 (17.0) | 20 (16.8) | 19 (22.1) | 18 (22.5) | NA | NA | NA | NA | NA |
| Missing n (%) | 0–19 (0–12.1) | 0–14 (0–10.1) | 0–12 (0–9.8) | 0–10 (0–11.2) | 0–8 (0–9.6) | 0–11 (0–17.5) | 0–11 (0–19.0) | 0–10 (0–19.6) | 0–7 (0–21.2) | 0–7 (0–22.6) |
Data at inclusion were complete for age, symptom duration, RF status, CRP, ESR, occurrence of erosions and treatment with sDMARDs and corticosteroids. Missing data for HAQ, DAS28 and VAS global and pain were 0.6% for women and none for men. 12.1% of the women and 17.5% of the men had missing data for anti-CCP. 3.2% of both women and men had missing data on BMI, 5.1% and 1.6%, respectively, on smoking history and 3.8% and 0%, respectively, on treatment with calcium, D-vitamin and bisphosphonates. 1.9% of the women had missing data on menopausal status and 3.2% on treatment with HRT.
anti-CCP, anticyclic citrullinated protein; bDMARDs, biological disease-modifying antirheumatic drugs; BMI, body mass index; CRP, C reactive protein; DAS28, Disease Activity Score-28 Joints; DXA, dual-energy X-ray absorptiometry; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; HRT, hormone replacement therapy; NA, not applicable; RF, rheumatoid factor; sDMARDs, synthetic disease-modifying antirheumatic drugs; VAS, Visual Analogue Scale.